Lexington, Mass.-based startup acquires U.S. marketing rights to prescription anti-obesity drug D-fenfluramine from France's Les Laboratories Servier. Interneuron plans to submit an IND for the serotonin release reuptake inhibitor in "late 1990" as a treatment to suppress carbohydrate craving that can be associated with obesity. Servier currently markets the product in France as an appetite suppressant under the brandname Isomeride. The drug is approved in 30 countries. The neurological R&D firm, which holds licenses for compounds from MIT, was started in 1988 and completed its initial public offering in March.
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.